eryaspase + gemcitabine + carboplatin

**eryaspase + gemcitabine + carboplatin** is an experimental combination regimen composed of three drugs: - **Eryaspase**: a recombinant L-asparaginase enzyme encapsulated within erythrocytes, designed to deplete extracellular asparagine, thereby starving tumor cells dependent on exogenous asparagine for growth. It is developed as an improved, longer-circulating, less immunogenic alternative to traditional L-asparaginases, and has been studied primarily in pancreatic and other solid tumors. - **Gemcitabine**: a nucleoside analog DNA synthesis inhibitor (antimetabolite) that causes cell death by inhibiting DNA replication. Approved mainly for solid tumors, including pancreatic, lung, breast, and bladder cancer[2][4][5][6]. - **Carboplatin**: a platinum-based DNA crosslinking agent that inhibits DNA synthesis and function, leading to cell death. Used broadly in solid tumors for patients where cisplatin toxicity is a concern[2][4][5][6]. This combination is under investigation in early phase clinical trials; gemcitabine + carboplatin is established in several indications for solid tumors, but eryaspase is at a more experimental stage, and there is limited direct clinical efficacy data available for this specific triplet regimen.

Other names

L-asparaginase erythrocyte encapsulatedgemcitabinecarboplatin